Center Laboratories Management

Management criteria checks 1/4

Center Laboratories' CEO is Su-Chi Wang, appointed in Oct 2023, has a tenure of 1.08 years. directly owns 0.18% of the company’s shares, worth NT$65.81M. The average tenure of the management team and the board of directors is 1.9 years and 2.8 years respectively.

Key information

Su-Chi Wang

Chief executive officer

NT$4.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	1.1yrs
CEO ownership	0.2%
Management average tenure	1.9yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Nov 20

CEO

Su-Chi Wang

1.1yrs

Tenure

NT$4,722,000

Compensation

Ms. Su-Chi Wang is Chairman of Lumosa Therapeutics Co. Ltd. from May 14, 2024. Ms. Wang Serves as Chief Executive Officer, Operations Management Office & Investment Office at Center Laboratories, Inc. sinc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Su-Chi Wang	CEO, Chief Investment Officer	1.1yrs	NT$4.72m	0.18% NT$ 65.8m
Min-Li Lien	Assistant Vice President of Legal Affairs Department	1.8yrs	NT$2.30m	no data
Jui-Pao Hsu	General President of Pharmaceutical Business	1.1yrs	NT$3.47m	0.68% NT$ 249.0m
Ching-Yu Tang	Head of Corporate Governance	no data	NT$1.87m	no data
Chiun-Yu Lin	Plant Director	7.8yrs	NT$2.28m	no data
An-Ni Mao	Manager of Finance & Accounting Department	1.9yrs	no data	no data
Hsiu Yueh Lin	Director of Administration Department	26.3yrs	no data	no data

1.9yrs

Average Tenure

Experienced Management: 4123's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Su-Chi Wang	CEO, Chief Investment Officer	2yrs	NT$4.72m	0.18% NT$ 65.8m
Mei-Yueh Ho	Independent Director	4.4yrs	NT$735.00k	no data
Chun-Hong Chen	Director	4.4yrs	NT$55.00k	no data
Bo Zhi Zhang	Director	2.8yrs	no data	0.29% NT$ 106.7m
Jialing Lin	Director	2.8yrs	no data	0.71% NT$ 261.2m
Chang-Hai Tsai	Director	2.5yrs	NT$55.00k	no data
Pei zhen Cai	Director	2.8yrs	no data	no data
Shi Jun He	Independent Director	2.8yrs	no data	no data

2.8yrs

Average Tenure

Experienced Board: 4123's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Center Laboratories Management

Management criteria checks 1/4

Key information

Recent management updates

Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent Director

Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024

Center Laboratories, Inc. Announces Executive Appointments

Center Laboratories, Inc. Announces Management Changes

Less than half of directors are independent

Center Laboratories, Inc. Elects Directors

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.38 (vs NT$1.49 loss in 3Q 2023)

Center Laboratories, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: NT$0.10 loss per share (vs NT$1.43 loss in 2Q 2023)

Center Laboratories, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.43 per share

First quarter 2024 earnings released: NT$0.78 loss per share (vs NT$1.52 profit in 1Q 2023)

Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent Director

Center Laboratories, Inc. to Report Q1, 2024 Results on May 13, 2024

Center Laboratories, Inc., Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released: NT$1.50 loss per share (vs NT$0.16 profit in FY 2022)

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: NT$1.49 loss per share (vs NT$1.68 loss in 3Q 2022)

Upcoming dividend of NT$0.99 per share at 1.9% yield

Second quarter 2023 earnings released: NT$1.57 loss per share (vs NT$0.31 loss in 2Q 2022)

Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023

Full year 2022 earnings released: EPS: NT$0.17 (vs NT$3.14 in FY 2021)

Center Laboratories, Inc. Announces Executive Appointments

Center Laboratories, Inc. Announces Management Changes

Less than half of directors are independent

Upcoming dividend of NT$2.43 per share

Second quarter 2022 earnings released: NT$0.36 loss per share (vs NT$2.42 profit in 2Q 2021)

Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021

Center Laboratories, Inc. Elects Directors

First quarter 2022 earnings released: EPS: NT$2.69 (vs NT$4.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$3.60 (vs NT$7.73 in FY 2020)

Center Laboratories, Inc., Annual General Meeting, May 20, 2022

Third quarter 2021 earnings released: NT$1.61 loss per share (vs NT$1.90 profit in 3Q 2020)

Upcoming dividend of NT$1.50 per share

Second quarter 2021 earnings released: EPS NT$2.66 (vs NT$2.88 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$4.63 (vs NT$0.48 in 1Q 2020)

Full year 2020 earnings released: EPS NT$8.50 (vs NT$0.68 loss in FY 2019)

Center Laboratories, Inc., Annual General Meeting, May 28, 2021

New 90-day low: NT$61.90

New 90-day high: NT$72.20

We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Third quarter 2020 earnings released: EPS NT$2.09

New 90-day low: NT$65.20

New 90-day low: NT$68.70

First half earnings released

Upcoming Dividend of NT$1.43 Per Share

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure